Proven to extend overall survival in patients with 1L GC/GEJC and PD-L1 scores ≥1%1
Key Efficacy Outcome: OS in PD-L1 ≥1%
15.0 months of median overall survival with TEVIMBRA + chemotherapy vs 12.8 months with placebo + chemotherapy
3-Year Exploratory Follow-Up: OS in PD-L1 ≥1%
Overall survival sustained over 3 years4
~1 in 5 patients were still alive at 3 years with TEVIMBRA + chemotherapy vs ~1 in 8 with placebo + chemotherapy
The 3-year OS analysis was exploratory in nature and was not powered to show statistical significance. Landmark OS rates were estimated using the Kaplan-Meier method.
Subgroup Analyses: OS in PD-L1 ≥1%
A consistent trend in overall survival favoring TEVIMBRA + chemotherapy across multiple key subgroups4
TEVIMBRA + chemotherapy:
- Is the first and only treatment with favorable survival data for patients with peritoneal metastases in trials using a PD-L1 score cutoff of ≥1%; HR: 0.81 (95% CI: 0.65-1.01)4-7
- Showed consistent OS trend regardless of race
Efficacy analyses were descriptive only.
1L, first line; dMMR, deficient mismatch repair; ECOG, Eastern Cooperative Oncology Group; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HR, hazard ratio; MMR, mismatch repair; mOS, median overall survival; MSI, microsatellite instability; MSI-H, microsatellite instability high; MSI-L, microsatellite instability low; MSS, microsatellite stable; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; pMMR, proficient mismatch repair; PS, performance status.
References: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
4. Moehler M, Oh DY, Kato K, et al. Adv Ther. 2025;42(5):2248-2268.
5. Rha SY, Oh DY, Yañez P, et al; KEYNOTE-859 Investigators. Lancet Oncol. 2023;24(11):1181-1195. doi:10.1016/S1470-2045(23)00515-06 Published correction appears in Lancet Oncol. 2024;25(12):e626. doi:10.1016/S1470-2045(24)00650-8
6. Janjigian YY, Ajani JA, Moehler M, et al. J Clin Oncol. 2024;42(17):2012-2020. doi:10.1200/JCO.23.01601
7. Shitara K, Moehler M, Ajani J, et al. Poster presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 18-20, 2024; San Francisco, CA. Poster Bd E6.